Posted inDiabetes & Endocrinology Specialties
Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial
The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight in Asian adults with obesity (BMI ≥25 kg/m²), supporting its safety and guideline inclusion in these populations with unique BMI thresholds.